In an interview with BioWorld, Ceros Financial Services CEO Mark Goldwasser predicted significant changes in the financing market for med-tech companies in the coming year. While special purpose acquisition company (SPAC) deals are not anticipated to return to 2022 levels, Goldwasser expects “we’re going to see a lot of transactions out of big strategics” and a rally in the equity market in the first half of 2023.

Ceros Capital Markets completed a $15 million series D funding round for Pristine Surgical LLC, its latest major investment in the medical device space. The funds will be used to advance the commercialization of Pristine’s single-use visualization platform for surgical and diagnostic endoscopic procedures.